| Brain Organoid Neurons | |
|---|---|
| Lineage | Stem Cell > Organoid > Brain Organoid |
| Markers | SOX2, NESTIN, TUJ1, MAP2, CTIP2, SATB2 |
| Brain Regions | In Vitro - Multiple Regional Identities |
| Disease Relevance | Alzheimer's Disease, Parkinson's Disease, Autism, Schizophrenia |
Brain Organoid Neurons is an important cell type in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Brain organoid neurons are three-dimensional, self-organizing cultures derived from human pluripotent stem cells (hPSCs) that recapitulate aspects of human brain development and structure[1]. These in vitro models contain various neuronal subtypes, glial cells, and progenitor populations that form neural networks exhibiting spontaneous electrical activity[2]. Brain organoids represent a transformative technology for studying neurodevelopment, neurodegeneration, and therapeutic drug discovery.
| Database | ID | Name | Confidence |
|---|---|---|---|
| Cell Ontology | CL:1001579 | cerebral cortex glial cell | Medium |
| Taxonomy | ID | Name / Label |
|---|---|---|
| Cell Ontology (CL) | CL:1001579 | cerebral cortex glial cell |
Cerebral organoids develop cortical-like structures with distinct ventricular zones and outer radial glial cells. They contain pyramidal neurons and interneurons that form functional synaptic connections[3].
Midbrain organoids contain dopaminergic neurons, serotonergic neurons, and melanized neurons resembling the substantia nigra. These are particularly relevant for Parkinson's disease modeling[4].
Hypothalamic organoids contain neurons that regulate homeostatic functions including metabolism, sleep, and stress responses[5].
Whole brain organoids aim to model multiple brain regions in a single structure, enabling study of region-specific interactions and long-range neural connectivity[6].
Brain organoids derived from patients with familial Alzheimer's disease mutations exhibit amyloid-beta accumulation, tau pathology, and synaptic loss within months of culture[7]. These models allow investigation of disease mechanisms and testing of anti-amyloid and anti-tau therapeutics.
Midbrain organoids containing dopaminergic neurons show vulnerability to alpha-synuclein aggregation and mitochondrial dysfunction, modeling key pathological features of Parkinson's disease[8].
Organoid platforms enable screening of compound libraries for efficacy in modulating disease phenotypes, providing human-relevant data earlier in the drug development pipeline[9].
Vascularization: Lack of functional blood vessels limits organoid size and survival
Maturation: Neurons in organoids often remain at a fetal-like developmental stage
Variability: Significant batch-to-batch variation affects reproducibility
Lack of immune cells: Absent microglia and infiltrating immune cells affect disease modeling
iPSC-Derived Hippocampal Neurons
Cerebral Organoid Neurons
Midbrain Organoid Dopaminergic Neurons
Technologies Index
The study of Brain Organoid Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Lancaster et al. Cerebral organoids model human brain development and microcephaly (2013). 2013. ↩︎
Quadrato et al. Cell diversity and network activity in ESC-derived cortical organoids (2016). 2016. ↩︎
Camp et al. Human cerebral organoids recapitulate gene expression programs of fetal neocortex development (2015). 2015. ↩︎
Jo et al. Generation of dopaminergic neurons and pigmented epithelia from primate ES cells by stromal cell-derived inducing activity (2006). 2006. ↩︎
Merkel et al. Hypothalamic stem cells control ageing speed partly through exosomal miRNAs (2017). 2017. ↩︎
Birey et al. Assembly of functionally integrated human forebrain spheroids (2017). 2017. ↩︎
Choi et al. A 3D human model that recapitulates pathological features of Alzheimer's disease (2014). 2014. ↩︎
Sanchez-Danes et al. Disease-specific phenotypes in dopamine neurons from human iPSCs with familial Parkinson's disease (2012). 2012. ↩︎
Skaper et al. Disease-modifying drug discovery for Alzheimer's disease: targeting the amyloidogenic pathway (2018). 2018. ↩︎